Related Experiment Video

Updated: Sep 17, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K

Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer

Amr Ali Mohammed Abdelgawwad Wl-Sehrawy1, Mahmood Yaseen Mukhlif2, Aysar Ashour Khalaf3

  • 1Department of Internal medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt.

Seminars in Oncology
|June 27, 2025
PubMed

Insights

Olaparib resistance in prostate cancer is a major challenge. Understanding molecular mechanisms like DNA repair pathway alterations and epigenetic changes is key to developing new combination therapies and biomarkers for better patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Olaparib, a PARP inhibitor, shows efficacy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair gene mutations.
  • Acquired and intrinsic resistance limit Olaparib's long-term therapeutic value.
  • Understanding resistance mechanisms is crucial for advancing prostate cancer treatment.

Purpose of the Study:

  • To investigate the molecular mechanisms of acquired and intrinsic resistance to Olaparib in prostate cancer.
  • To identify key pathways and genetic alterations contributing to Olaparib resistance.
  • To inform the development of novel therapeutic strategies against resistant prostate cancer.

Main Methods:

  • Review of current literature on Olaparib resistance in prostate cancer.
  • Analysis of molecular pathways involved in DNA damage repair and cell cycle regulation.
  • Exploration of genetic mutations and epigenetic modifications associated with resistance.

Main Results:

  • Resistance mechanisms include restoration of homologous recombination (HR) repair via secondary BRCA2 mutations, loss of 53BP1/REV7/Shieldin complex activity, and activation of alternative DNA repair pathways.
  • Cell cycle checkpoint alterations and epigenetic changes contribute to therapy resistance.
  • Multiple molecular routes lead to Olaparib resistance in prostate cancer.

Conclusions:

  • Knowledge of resistance mechanisms enables the design of combination strategies targeting compensatory pathways and epigenetic modifiers.
  • Biomarker discovery is essential for guiding personalized treatment choices and optimizing sequential therapies.
  • Overcoming Olaparib resistance will improve clinical outcomes for advanced prostate cancer patients in the precision medicine era.
Keywords:
OlaparibPARP inhibitorProstate cancerTherapymCRPC

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.8K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.2K